

Citeline 使用介绍

R&D统一数据平台

Robert Wu
客服及产品培训专员
Robert_wu@informa.com



Informa生命科学智库



Informa医药数据库一览

□ Pharma Intelligence 系列

- **Trialtrove**
- **Trialpredict**
- **Sitetrove**
- Pharmaprojects
- Datamonitor Healthcare
- Biomedtracker
- Meddevicetracker
- Pharmapremia
- Medtrack
- Strategic Transactions
- Pharma consulting

药物研发
(R&D)
统一数据平台



- Citeline系列一览
- 分析师咨询服务 (Ask the Analyst)
- 商业应用
- 各产品一览:
 - ❖ Trialtrove
 - ❖ Trialpredict
 - ❖ Sitetrove
 - ❖ Pharmaprojects
- 主要功能
- 调研案例
- 客服支持
 - ❖ 辅助链接

Citeline系列一览

R&D统一数据平台

专注于R&D领域的全方位咨询服务

运用全球领先的药物、临床试验、研究人员及地点的统一线上平台，进一步优化临床成本及结果！

Trialtrove

以最全面、准确、及时的临床试验信息，按时及预算制定最佳临床方案

Trialpredict

通过业内最丰富的受试者募集及临床试验时间数据，对比及分析您的临床试验方案

Sitetrove

查询全球最佳研究人员及地点信息，进一步降低研发风险及成本

Pharmaprojects

使用最值信赖的研发药物数据库，全面追踪全球范围内从临床前至上市的R&D管线

APIs

通过API把上列所有数据库导入至客户指定数据系统

Custom Analytics

通过深入分析，提供订制分析师调研服务

✓ 幕后拥有超250名深知客户研发挑战的业内专家及分析团队，所有原始数据均转化成最具价值的研发情报

✓ 完整报告覆盖：

- 74,000+ 药物
- 299,000+ 临床试验
- 429,000+ 研究人员
- 162,000+ 研究地点

避免研发失败的巨大代价

考虑研发成本：

¹新药研发总成本约5-25亿美元…
同时伴有98%失败率

Citeline系列将在研发各领域提供专业帮助

范围涵盖研发趋势、临床研究人员及地点选择，以及临床项目计划等…



Citeline综合智库可助您作出更经济及高效的明智决策

- ✓ 作出可行或不可行的正确决策（同时降低失败机率）
- ✓ 设计无须额外临床试验的临床项目
- ✓ 减低受试者募集及临床试验用时

Citeline – 降低研发用时及成本，同时优化临床方案

- ✓ 全面了解全球研发药物及临床试验格局及竞争趋势
- ✓ 根据评估竞争对手的药物信息及临床试验方案，进一步优化研发计划及临床方案
- ✓ 通过分析临床试验项目的目标终点及临床结果，避免日后作出不必要的临床方案修订
- ✓ 通过查阅以往、当前及未来的临床试验、研发人员及地点的相关活动及研发密度等信息并提前作出可行性分析，以便选择合适的国家进行临床试验
- ✓ 数千条衡量基准均可一秒检索相关信息，以便优化临床计划及时间方案
- ✓ 识别最具资历及研发记录、并符合您研究方案的临床研究人員、地点及机构
- ✓ 降低选择Non-Enrolling Sites的风险
- ✓ 评估相似临床方案的临床试验时间信息，以便作出更准确的预算管理及时预测
- ✓ 准确追踪及评估竞争对手的研发药物与临床试验进展

业内最全面及准确的全球R&D综合数据库

250+

业内专家

全面追踪、分析、扩大研发数据

43,000+

信息来源

持续增加中

301,000+

临床试验完整报告

(一至四期)

75,000+

全球研发药物完整报告

(记录超过35年的研发历程)

431,000+

临床研究人員

(通过以往经验进行等级排行)

162,000+

临床研究地点

(通过类型及临床经验区分)

Citeline分析师团队



拥有超250名常驻全球主要市场的各疾病领域专家团队
了解您的独特需求



精通各研发领域

跨产品的分析师团队通力合作，
统一收集、评估及分析从临床前
至上市的一切研发信息




多年经验值得信赖

累积数千年的从业及专业经验，
分析师团队可提供值得信赖的
专业见解



业内顶级分析

以全面、透明及独立的
视角作出专业分析



数据均由业内专家验证，并配有无限限制分析支持

无可比拟的数据“质”与“量”

涵盖临床试验、研究人员及地点，以及药物研发管线

原始数据均由业内专家亲自确认、分析及增强

配有无限限制分析师咨询服务

引用

超43,000条网上资源

- 基于事件的更新
- 反复验证关键信息来源
- 排除重叠数据

分析

分析师专业见解是关键所在

增强

通过业界及各疾病领域专家分析与运用所有相关额外补充数据，最大程度优化信息范围及质量

编辑

信息均可在线上统一平台查询，各种信息（如：药物、临床试验、受试者募集及临床用时、研究人员及地点等）均以相互连接的方式编辑及排列

内容范围涵盖整个公共领域

主要信息来源 – 目前引用超过43,000个信息来源并持续增长


- 超过70个来自各国或地区的临床试验注册机构（如：ClinicalTrials.gov, EUCTR, JAPIC, ChiCTR等）
- 超过90个其他临床试验资讯来源（如：申办方注册信息、合作机构、主要医疗中心）
- 超过5000个企业信息（全面涵盖管线、新闻报道、投资者，以及其他网页）
- 所有主要医疗会议（超过250个会议）
- 新闻资源、投资者演讲、美国证监会文件，以及公司年度报告等
- 各国医疗及卫生机构的官方网页
- 医学杂志及论坛
- USAN与INN lists, eMolecules, ChemSpider, & ChemIDplus
- 其他线上资源，如：Gene（前身为EntrezGene）、PubMed，以及Espacenet等

引用额外信息来源以确保全面市场情报覆盖

那些看似无多关联的信息资源也能提供具有价值的见解：

- 研究中心网站
- 社区医院网站
- 大学研究规章/IRB审核批准目录
- 患者权益相关网站
- 调访研究报告 (Primary Research)

Total Trialtrove Cited Sources by Therapeutic Area



- 内容持续更新
- 所有资料均提供完整出处信息，以确保查证的透明性

分析师咨询服务 (Ask the Analyst)

与业内领先的分析师团队进行直接联系

拥有超过250名高资历（硕士及博士学位）并充分了解您独特需求的资深专家团队...



专家解答 – 为订阅者独家提供可行的个性化咨询服务，其中包括定制的数据收集及调研支持



高效答复 – 通过透明及可查证的信息来源，提供完整解答以便作出正确决策



跨产品调研支持 – 引用我司其他医药产品，提供完整资讯辅助



Got a question?
Ask the Analyst™

业界及各疾病领域专家团队鼎力相助

难题待解?

直接点击“Ask the Analyst”按钮向分析师团队进行提问!

您将获得针对您具体需求的一对一分析师咨询支持 – 分析师团队每天负责对所有信息进行整编、验证及分析,并向您提供所需帮助。

分析师咨询服务
(Ask the Analyst)

Pharmaprojects

例: “我想了解作用机制“AB-024”的最新状况。”

Trialtrove

例: “我想了解所有在欧盟或日本市场目前处于计划中或正在进行中并有应用Avastin的临床试验列表, 其中包括开始日期、结束日期, 以及目标及实际受试者募集状况。”

Sitetrove

例: “哪些常驻伦敦的临床研究人员及地点曾在过去两年有HER2阳性乳腺癌临床三期的研究经历?”

Trialpredict

例: “我想通过查阅名为【HES 130/0.4 in balanced electrolyte solution (Volulyte®) vs. balanced crystalloid solution in patients undergoing elective abdominal surgery】的临床试验作比照调研, 不知如何检索?”

The screenshot shows the Citeline Pharma Intelligence web application. At the top, there are navigation tabs for 'Trialtrove', 'Sitetrove', and 'Pharmaprojects'. A red box highlights the 'Ask the Analyst' button in the top right corner. Below the navigation, there is a search bar for drugs. The main content area displays a list of drugs with columns for 'Generic Drug Name', 'Drug Names', and 'Global Status'. A modal window titled 'Ask the Analyst' is open, showing a form for submitting questions to experts. The form includes a text area for describing the information needed and a 'Send' button.

医药领域 实际应用例子

Citeline – 常见应用

临床试验管理 (Clinical Operations)

- 进行可行性评估及目标国家或地点选择
- 获取所有优化临床项目方案的所需情报
- 比对调研临床试验时间表

药物研发 (Research & Development)

- 识别与自身产品管线拥有相似化学结构、靶点或作用机制的药物
- 追踪进入研发阶段的创新靶点药物

监管方资讯 (Regulatory)

- 掌握申请过优先审查的药物
- 评估竞争对手对于监管方的研发战略布局

商业发展 (Business Development)

- 发掘潜在合作机遇及新疾病领域研发战略
- 通过各种检索条件（如：公司、适应症、作用机制或靶点），评估竞争市场格局
- 分析重大市场事件（如：研发终止、上市、批准或孤儿药状态等）

临床试验管理

Clinical Operations

Citeline如何帮助临床试验管理及评估可行性？

Trialtrove

优化临床用时及成本管理
提高投资回报率及研发成功率

- 评估竞争对手临床试验方案，优化自身临床项目
- 分析临床终点及结果
- 掌握所有临床试验及其研究地点，评估当前临床试验密度以作可行性分析
- 通过Trialpredict快速查阅受试者募集及临床用时数据，进一步优化自身临床项目方案及创建最佳临床时间表

Sitetrove

识别最佳临床研究人选及地点
降低成本及潜在风险

- 发掘拥有相关资历并符合自身临床方案的最佳临床研究人选
- 识别最具资历临床研究人员的所在地
- 制定符合自身临床试验的最佳研究人才及机构列表
- 降低选择Non-Enrolling Sites的风险

Pharmaprojects

通过深入比对调研药物、研发趋势及里程碑，优化自身临床战略布局

- 掌握竞争对手研发项目的关键里程碑及研发时间表
- 通过分析特定药物类别的相似研发方案，验证自身的研发战略
- 了解比对药物的各国或地区上市状态，为选择目标上市地提供更多资讯

药物研发及商业发展

R&D and B&D

Citeline如何为R&D及B&D提供帮助?

- 预测潜在竞争风险及研发战略布局，发掘市场机遇
- 掌握哪些竞争对手在目标疾病领域内的研发动态，并评估其研发方案
- 分析市场研发趋势与进行市场进入调研
- 了解竞争对手的研发战略布局及其产品的研发时间表

监管方资讯 Regulatory

Citeline如何提供药物研发的监管方资讯？

- 掌握申请过优先审查的药物
- 评估竞争对手对于监管方的研发战略布局
- 了解竞争对手的研发战略、预期申请递交时间及临床时间表

实际研究案例：

“我司的抗生素产品即将进入临床并极有可能应用至多种细菌感染疾病，不知哪个适应症可最快获得初次批准？”

详情查阅 – [Link to Citeline Regulatory Case Study](#)

Pharmaprojects

研发药物数据

通过业内最值得信赖的药物研发数据，全面追踪全球R&D管线从临床前至上市的研发动态

利用超过35年的药物研发数据 – 掌握全球生物制药市场的研发趋势与潜在机会及风险

- 完整分析所有疾病领域，从临床前至上市的全球药物研发历程及趋势
- 查阅业界顶级的历史数据，其中包括1995年至今的研发趋势图表
- 进一步优化商业发展及合作战略布局，同时发掘潜在机遇
- 通过各种筛选功能（如：公司、适应症、作用机制及靶点等），进一步评估特定竞争市场格局
- 发掘全新疾病领域研发战略
- 分析主要市场事件（如：研发终止、上市、批准等）
- 识别拥有相似化学结构或作用机制的药物
- 识别拥有特定药物来源（如：生物制剂）或靶点（如：PD-L1）的药物
- 利用合计75年以上的分析师经验及专业知识，与分析师团队直接联系

业界最悠久及最值得信赖的药物研发数据

43,000+
公共领域引用来源
(经分析团队验证的各疾病领域数据)

75,000+
药物完整报告

16,000+
处于研发态势的药物
(一年内有更新)

1,600+
适应症

570+
罕见疾病

3,000+
靶点

3,600+
作用机制

Pharmaprojects如何能帮到您？

商业发展 (Business Development)

- 识别潜在合作机遇 (In/out-licensing)
- 分析药物研发历程
- 发掘全新疾病领域研发战略

竞争分析 (Competitive Intelligence)

- 通过各种筛选条件 (如: 公司、适应症、作用机制或靶点等), 评估竞争市场格局
- 分析重大市场事件 (如: 研发终止、上市、获批或孤儿药状态等)

研究与开发 (Research & Development)

- 哪些药物拥有相似的化学结构或作用机制?
- 哪些应用创新靶点的药物进入了研发阶段?

完整涵盖临床前至上市信息...

全面覆盖1980年至今所有商用或处方用的全球各疾病领域药物研发信息 – 其中包括：制药、疫苗、新型或重新配方药物及技术，以及特定体内诊断



超过75,000个完整药物报告

- 研发方及合作方信息
- 所有应用适应症及最高临床阶段信息
- 重大事件综述 – 全面追踪关键事件（如：研发状态变动、孤儿药申请批准或首次上市等）
- 作用机制及靶点
- 全球各国上市或获批状态
- 是否有合作空间？
- 药物化学信息（如：药物来源、化学名或化学结构等）
- 研发信息
- 临床前信息

Pharmaprojects 药物报告涵盖范围?

Drug

obeticholic acid

6-ECDCA; 6-ECDCA (capsule); 6-ECDCA (tablet); 6alpha-ethylchenodeoxycholic acid; DSP-1747; DSP-1747 (capsule); DSP-1747 (tablet); INT-747; INT-747 (capsule); INT-747 (tablet); obeticholic acid; obeticholic acid (capsule); obeticholic acid (tablet); Ocaliva

Drug Summary

Global Status: Launched
Development Status: Active


Latest Change: Approval in Australia and Israel as Ocaliva for primary biliary cirrhosis (PBC) reported
Latest Change Date: 2018/12/10

Summary
Obeticholic acid (INT-747) is an orally-active analogue of the natural human bile acid CDCA (chenodeoxycholic acid), developed by Intercept Pharmaceuticals (Genextra) as a first-in-class farnesoid X receptor (FXR) agonist for the treatment of primary biliary cirrhosis (PBC). It is also under development for the treatment of non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) (Scrip Daily Online, 6 Sep 2004, S00856390; Company Web Page, Intercept, 21 Jun 2007; USAN Web Page, 5 Nov 2008; Press release, Intercept Pharmaceuticals, 8 Oct 2014, <http://ir.interceptpharma.com/releasedetail.cfm?ReleaseID=875121>; Company pipeline, Sumitomo Dainippon Pharma, 29 Jan 2015, <http://www.ds-pharma.com/rd/clinical/pipeline.html>).

- Drug Summary
- Company Data
- Diseases
- Activity
- Event History
- Chemical data
- Country data
- Trialtrove Trials
- Marketing
- Licensing
- Phase III
- Phase II
- Phase I
- Preclinical
- Supporting URLs

Company Data		
Originator		
Name	Country	Status
Intercept Pharmaceuticals (part of Genextra)	USA	Launched
Licensee		
Name	Country	
Sumitomo Dainippon Pharma	Japan	
Diseases		
Name	Status	
Cirrhosis, primary biliary	Launched	
Non-alcoholic steatohepatitis	Phase III Clinical Trial	
Hypertension, portal	Phase II Clinical Trial	
Primary sclerosing cholangitis	Phase II Clinical Trial	
Biliary atresia	Phase II Clinical Trial	
Diarrhoea, unspecified	Preclinical	

Chemical data	
Origin	Chemical, synthetic
NCE	Yes
CAS registry number	459789-99-2
Molecular Formula	C28H44O4
Molecular Weight	420.63
logP	4.52
Chemical Structure	



H Bond Donors	3
H Bond Acceptors	4
Rotatable Bonds	5
Chemical Name	(4R)-4-[(3R,6R,7R,10S,13R)-6-ethyl-10-hydroxyheptadecahydro-3H-cyclopenta[b]pyridin-3-yl]pentanoic acid
Chemical Structure (SMILES format)	CC[C@@H]1[C@@H](O)C2C(CCC[C@@H]1)C(C)C

Trialtrove Trials					
Trialtrove Trial Count: 27					
Phase	Disease	Sponsor	Drugs tested	Protocol/Trial ID	Status
(N/A)	ClinicalTrials.gov	University of Aarhus	obeticholic acid; Placebo	NCT02533276; OCAPBC	Open
I	Hepatic Fibrosis, NAFLD	Sumitomo Dainippon Pharma (Dainippon Sumitomo)	obeticholic acid	Trial/TroveID-167308	Completed
I	Hepatic Fibrosis	Genextra/Intercept Pharmaceuticals	obeticholic acid	Trial/TroveID-336296	Completed
I	Hepatic Fibrosis, NAFLD	Genextra/Intercept Pharmaceuticals	obeticholic acid (tablet)	Trial/TroveID-245334; 747-104; NCT01914562	Completed
I	Hepatic Fibrosis, NAFLD	Genextra/Intercept Pharmaceuticals	obeticholic acid	Trial/TroveID-249887	Planned
I	Hepatic Fibrosis, NAFLD	Genextra/Intercept Pharmaceuticals	obeticholic acid	Trial/TroveID-186863	Completed
I	ClinicalTrials.gov	Sahlgrenska University Hospital, Sweden	obeticholic acid; Obeticholic acid placebo	NCT02532335; OCAPUSH	Open
I	Hepatic Fibrosis, NAFLD	Genextra/Intercept Pharmaceuticals	obeticholic acid	Trial/TroveID-186989; 747-105; NCT01933503	Completed
II	NAFLD	Genextra/Intercept Pharmaceuticals	atorvastatin calcium; obeticholic acid	Trial/TroveID-369972; 747-209; CONTROL; NCT02613956	Completed
II	Hepatic Fibrosis	Genextra/Intercept	obeticholic acid	Trial/TroveID-162443; 747-201;	Completed

Pharmaprojects 药物报告涵盖范围?

Drug

- Drug Summary
- Company Data
- Diseases
- Activity
- Event History**
- Chemical data
- Country data
- Trialtrove Trials
- Marketing
- Licensing
- Phase III
- Phase II
- Phase I
- Preclinical
- Supporting URLs

Event History

Date	Status	Description
2018/10/31	New Approval	Australia & Israel; Cirrhosis, primary biliary
2017/05/25	New Approval	Canada; Primary biliary cholangitis when used in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA
2017/01/15	New Launch	The EU; Primary biliary cholangitis
2016/12/14	New Approval	The EU; Primary biliary cholangitis
2016/09/19	Expedited Review Designation Granted	Canada; Primary biliary cirrhosis; Priority review
2016/09/19	New Filing	Canada; for the treatment of primary biliary cholangitis, also referred to as primary biliary cirrhosis (PBC), when used in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
2016/06/15	First Launch	NAS; USA; PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA
2016/05/27	First Approval	The US; Primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA
2015/10/15	Disease Phase Change	Biliary atresia; Phase II Clinical Trial
2015/09/28	Disease Phase Change	Non-alcoholic steatohepatitis; Phase III Clinical Trial
2015/08/31	Expedited Review Designation Granted	The US; Primary biliary cirrhosis; Priority review
2015/08/05	New Disease	Biliary atresia


Marketing

- 上市批准
- 各类申请
- 孤儿药状态
- 各类优先审查申请
- 监管部门警告信

一键筛选、分析、查阅及下载


可下载的 交互式图表 功能

- ✓ 分析数据
- ✓ 快速筛选检索范围或结果
- ✓ 图表同步更新



可下载的 研发趋势图表 或列表功能

- ✓ 查阅并分析历史药物研发趋势，预估未来研发前景



主要功能

Citeline线上平台界面（各模块拥相同设计）

The screenshot displays the Citeline online platform interface. At the top, there is a navigation bar with the 'informa' logo and a dropdown arrow. Below this, the 'Citeline' logo is followed by navigation tabs for 'Trialtrove', 'Sitetrove', and 'Pharmaprojects'. On the right side of the navigation bar, there are links for 'Saved Searches & Alerts', 'Help', 'My profile', 'Log out', and a red button labeled 'Ask the Analyst'.

The main search area is highlighted with a red box and contains a search bar with the placeholder text 'Enter a single term to lookup trials by name, disease, status, location, etc.'. A red stamp '快速检索栏' (Fast Search Bar) is overlaid on this area.

Below the search bar, a sidebar on the left is highlighted with a red box. It contains a 'Filter categories' section with a 'Trial' category expanded. Under 'Trial', there are several filter options: 'Details', 'Trial Title', 'Protocol/Trial ID', 'Trial Phase', 'Trial Status', 'Trial ID', 'Disease', 'Therapeutic Area', and 'Disease Disease'. A red stamp '检索条件选择' (Search Condition Selection) is overlaid on this sidebar.

The main content area is highlighted with a green box and shows search results for '306,506 trials'. It includes a 'View related' section with links for 'Investigators (435,777)', 'Organizations (164,525)', and 'Drugs (76,016)'. There are buttons for 'Results', 'Timeline', 'Dashboards', and 'Map'. An 'Export' button is also present. The results are displayed in a table with columns: 'Trial Title', 'Protocol/Trial ID', 'Trial Phase', 'Trial Status', 'Therapeutic Area', 'Disease', and 'Select'. Two trial entries are visible:

Trial Title	Protocol/Trial ID	Trial Phase	Trial Status	Therapeutic Area	Disease	Select
Sustain virology response of Sofosbuvir and ribavirin for compensated liver cirrhosis with genotype 2 hepatitis C infected patient	TrialTroveID-344097	IV	Completed	Infectious Disease	Infectious Disease: HCV	<input type="checkbox"/>
Accelerated Treatment of Endocarditis	H-18028566 NCT03851575 POETII POEIII NCT03821212	IV	Open	Infectious Disease	Infectious Disease: Sepsis	<input type="checkbox"/>


A 'feedback' button is located at the bottom right of the results area.

At the bottom left of the page, there is a footer with the number '31' and the text 'Pharma intelligence | informa'.

视觉逻辑搜索 (Visual Boolean Search)

方便修改，注重逻辑思维

- 指定每个连接词语该如何使用 (is, is not, contains, does not contain)
- 组合词语用于处理复杂逻辑思维
- 使用参数连接词 (and/or) 建立复杂搜索




- ✓ 无须再记住复杂的搜索配搭及结构
- ✓ 实时同步查看与验证检索结果
- ✓ 快速与准确地确认搜索条件，即便是储存或共享的检索

快捷搜索栏

快速查询相关数据

- 输入关键词
- 根据以上词语快速查询可用的搜索结果或搜索参数
- 单个或同时使用关键词检索与过滤搜索
- 搜索全文内容



- ✓ 节省时间
- ✓ 发现意想不到的搜索条件搭配方式
- ✓ 为不常使用的用户简化了检索

动态搜索与筛选

快速、轻松地搜索与筛选结果

- 通过扩展或缩小搜索条件列表轻松地查询结果
- 从列表中选择或通过关键词搜索快速找到搜索条件
- 实时查看查询结果

✓ 更快、更精准的搜索方式

✓ 对初用者或不常用用户来说更便捷，同时保留了资深用户的需求

Trial	Disease	↑	×
Trial Title	×	Therapeutic Area: Cardiovascular	
Trial Phase	Filter Disease		
Trial Status	Displaying 11 of 158 keywords		
Trial Start Date	Cardiovascular: (N/A)	+	
Therapeutic Area	Cardiovascular: Acute Coronary Syndromes	+	
Disease	Cardiovascular: Arrhythmia	+	
Patient Segment	Cardiovascular: Cardiomyopathy (Under Construction)	+	
MeSH Term	Cardiovascular: Congestive Heart Failure	+	
Protocol/Trial ID	Cardiovascular: Coronary Artery Disease	+	
Location	Cardiovascular: Dyslipidemia	+	
Region	Cardiovascular: Hemostasis/Hemophilia	+	
Country	Cardiovascular: Hypertension	+	
Drug	Cardiovascular: Peripheral Arterial Disease	+	
Therapeutic Class	Cardiovascular: Thrombotic Disorders	+	

大量导入搜索条件

轻松建立复杂的搜索列表

- 输入或上传搜索词列表
- 可用于MeSH、临床研究名称、疾病、患者群体、Protocol或Trial编号、国家等

- ✓ 节省时间
- ✓ 提升可靠性
- ✓ 导出结果后轻松自定义建立新的搜索列表，以便创建新的搜索

The screenshot shows a search interface with a left-hand navigation menu and a main content area. The navigation menu includes options like 'Open all | Close all', 'Filter categories', 'Drug', 'Details', 'Drug Names', 'Global Status', 'Development Status', 'Citeline Drug ID', and 'Disease'. The 'Drug Names' option is highlighted. The main content area shows a 'Drug Names' filter panel with a search input field containing 'Filter Drug Names' and an 'Add' button. Below the input field, it says 'Displaying 250 of 213,843 keywords'. A list of drug names is shown, including '(+)-12-oxocalanolide', '(+)-calanolide A', '(+)-calanolide B', '(+)-DDMS', '(+)-didesmethyisibutramine', and '(+)-discodermolide'. A red circle highlights the 'Add' button in the filter panel.

Drug Names: enter multiple keywords

Import from a spreadsheet

Spreadsheets should contain a single column of keywords exactly as they appear in the results table or export document. The file should be in XLS, CSV, or ODF format.

Select file to import from

and/or paste keywords

Separate keywords with line breaks. Keywords should be exactly as they appear in the results table or export document.


Keyword 1
Keyword 2
Etc.

Feedback

可下载的交互式图表显示功能 (Interactive Dashboards)

分析 > 修正 > 导出

- 随意选择显示部分或全部图表内容
- 随意切换图表或列表模式、以及选择显示前20或所有结果
- 一键导出至Excel格式以便修改或直接复制图表至演示资料
- 每当修改检索条件，图表即刻自动同步更新
- 点击图表内容即可加入至检索条件并同步更新



✓ 分析数据并快速优化检索及结果

✓ 立即更新您的演示资料

自定义视图选择与数据导出

自行定制观看结果方式

- 添加、删减或重新排列搜索结果栏目
- 导出所有或已选的栏目数据
- 向右滑动查看更多信息栏目
- 导出所有或已选信息
- 选择以表格或地图方式查看
- 搜索结果栏目内进一步筛选

3,482 trials View related: Trials | Investigators

Table Map


Column counts 50 results Show/Hide columns Export

Trial Phase	Disease	Trial Title	Protocol/Trial ID	Trial Status	Investigator
II	Infectious Disease: HIV	10493 - MK-0518 Intensification and HDAC Inhibition in Depletion of Resting CD4+ T Cell HIV Infection	10493, CID 0704, NCT00576290, NCT00614458, NIH R01 AI64074, P30 AI50410, P30AI050410, R01 AI64074, R01 AI45297, R01AI064074, RR00046, TrialTroveID-081414, U01 A125868, U01AI067854, U01AI125868	Terminated	
II	Infectious Disease: HCV	12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy	NCT00069511, TrialTroveID-012721, UT-231B-02:01	Completed	
III	Infectious Disease: HIV	1592U89 Open-Label Protocol for Pediatric Patients With HIV Infection	238E, CNA 3007, CNA3/3007, CNA A/B3007, CNA3007, NCT00002197, TrialTroveID-044210	Completed	GlaxoSmithKline (Glaxo Wellcome)
II	Infectious Disease: Respiratory Infections	3-arm Randomized Controlled Trial Assessing the in Vivo Effect of an Echinacea Purpurea on Immune Markers in Adults	10A1276, NCT01129128, TrialTroveID-127723	Completed	National Institutes of Health/National Center for Complementary and Alternative Medicine, University of Washington

Dropdown menu options:

- All
- Trials
- Trial ID
- Protocol/Trial ID
- Trial Title
- Trial Phase
- Trial Status
- Trial Start Date
- Trial End Date
- Last Modified Date
- Last Full Review
- Therapeutic Area


- ✓ 节省时间 – 无须导出内容再查看数据，也无须返回至筛选结果界面
- ✓ 提升准确性 – 通过同时查看关键数据、搜索条件，以及能随时调整搜索



资料连接

快速浏览相关记录

- 直接从临床研究名称右键点击另开网页，并直达相应资料
- 使用Navigation快速跳到所需信息



Drug Summary for **autologous FANG vaccine, Gradalis**

Back to search | Print Page | Displaying 72 of 132 | Previous | Next

- Drug Summary
- Company Data
- Diseases
- Activity
- Event History
- Chemical data
- Country data
- Marketing
- Licensing
- Phase III
- Phase II
- Phase I
- Supporting URLs
- Top

Drug Summary

Synonyms: autologous FANG vaccine, Gradalis; bi-shRNA furin and GMCSF augmented autologous tumor cell vaccine, Gradalis; bi-shRNafurin and GMCSF Autologous Tumor Cell Immunotherapy, Gradalis; engineered autologous tumor cell immunotherapy, Gradalis; FANG autologous tumour cell vaccine, Gradalis; FANG, Gradalis; gemogenovatucl-T; IND-14205; IND14205; Vigil, Gradalis

Global Status: Phase III Clinical Trial

Development Status: Active

Latest Change: Planned Phase III trial (CL-PTL-130) for Ewing's sarcoma reported

Latest Change Date: 2018/04/13

Summary

FANG vaccine is an autologous vaccine expressing rhGMCSF and the bifunctional RNAi effector, bi-shRNA furin, under development by Gradalis for the treatment of cancer. The GMCSF protein stimulates the immune system, while the furin bifunctional shRNA clocks furin protein activation via RNA degradation and translational inhibition (Company Web Page, Gradalis, 19 Oct 2011, <http://www.gradalisinc.com/>).

Company Data

Originator


Name	Country	Status
Gradalis	USA	Phase III Clinical Trial

保存与分享

随时随地分享及使用


Next Gen版本

- 只保存您觉得重要的搜索
- 可以对已存搜索起名
- 同一地方管理Trialtrove与Sitetrove的已存搜索



Trialtrove & Sitetrove 交互性地图功能 (Maps)

现即可查阅各国或地区在临床试验、研究人员或地点的情况及密度




- 通过各种检索条件（如：适应症或患者人群）准确识别出与您的研发方案匹配的完整竞争市场格局
- 发掘符合您要求并可用的研究人员或地点的集中地
- 查看各国或城市的结果数量
- 通过热点地图（Heat Map）完善您的检索范围

For more information on Citeline Next Generation contact your Account Manager or Client Success Manager

Trialpredict 时间线图表模式 (Timeline Dashboard)

快速查阅及评估临床试验竞争格局



- 通过临床阶段、预期或实际患者募集期、治疗期等信息，立即查阅所有符合要求的临床试验
- 快速识别有竞争力的研发时间段、评估临床研究战略、分析潜在患者人数
- 通过药物、作用机制、临床阶段、入选或去除条件、患者人群、申办方等条件，筛选并优化检索范围
- 通过药物、适应症、临床阶段、临床研究编号、研究状态，以及申办方Label，随意对图表进行修改

For more information on Citeline Next Generation contact your Account Manager or Client Success Manager

Sitetrove

研究人员及地点邮件提醒功能 (Alerts)

追踪及邮件提醒功能 (Watches and Alerts) - 掌握研发人员及地点情况与变化

- 追踪研究人员及机构、研发状态、研究人员首要附属机构，以及监管事件更新
- 对检索范围或个别信息设置自动邮件提醒功能，快速掌握新加的研究人员、地点或机构
- 自动获取提醒邮件，掌握所有重要事件更新

Date Saved	Name	Query	Total When Saved	Product	Action
2018/10/24 14:35	Oncology Triple Negative Breast	(Disease is Oncology: Breast) AND (Patient Segment is Breast: Triple receptor negative) AND (Specialty is Oncology)	6,977	Sitetrove - Organization	Watch Open Share Remove
2018/10/22 13:30	The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James (Arthur G. James Cancer...	(Organization ID is 34419)	1	Sitetrove - Organization	Watch Open Share Remove
2018/10/22 13:28	Callaghan, John T	(Investigator ID is 13295)	1	Sitetrove - Investigator	Unwatch Open Share Remove

Filter categories: Triple Receptor Negative Add

Organization: Breast: Triple receptor negative

Disease is Oncology: Breast

Displaying 1 of 1,631 keywords

Create your alert

Name your alert (optional)

Oncology Specialty Breast Triple Receptor Negative

Receive email alerts for this search

Cancel Create Alert

Organization Name: The University of Texas - MD Anderson
Organization Type: Academic Hospital / Clinic
Organization Country: United States

追踪候选研究人员及地点信息

追踪您雇用的研发人员进展及FDA视察结果，并与竞争对手进行比较

快速查阅研发人员及地点是否可用

Pharmaprojects

药物化学结构检索 (Chemical Structure Searching)

快速绘出化学结构搜索下部或相似的结构 – 无需安装额外插件

- 可简单画出结构，也可导入/导出化学结构
- 可通过下部结构 (sub-structure) 或相似度百分比进行检索
- 无需下载任何额外插件，适用于所有主流浏览器

直观的绘画工具
直接导入或导出资料

Powered by ChemAxon Marvin JS

Sub Structure Similarity 80%

34 drugs
View related: Trials | Investigators | Organizations

Chemical Structure is substructure of M182000 24 26 0 0 0 0 0 0 0 9999 V2000 4.3326 0.4125 0...

Export 50 results Show/Hide columns

Clinical Drug ID	Generic Drug Name	Drug Names	Development Status	Trial/Trial Count	Target	Summary	Marketing	Select
75921	esomeprazole magnesium DR + levosulpride ER	Nexpro L; esomeprazole magnesium DR + levosulpride ER; levosulpride ER + esomeprazole magnesium DR	Widely Launched	2	ATPase, H+K+ exchanging, alp... 5-hydroxytryptamine (seroton)... dopamine receptor D2	Nexpro L is a fixed-dose combination of esomeprazole magnesium and levosulpride, developed by Torrent Pharmaceuticals for the treatment of gastroesophageal reflux disease (GERD) (Clinical Trials Registry India Web Page, 23 Mar 2012, ...)	Approvals... oesophageal reflux (Indic... as Nexpro L (Company We... rent, 3 Sep 2015, https://www.pharma.com/the_gastroin...gl).	<input type="checkbox"/>
36948	esomeprazole + low-dose ASA	ASA + Nexium; ASA + esomeprazole; ASA + esomeprazole magnesium; Axanum; D-9613; D9613; Nexium + ASA; esomeprazole + ASA; esomeprazole + acetylsalicylic; esomeprazole + low-dose ASA; esomeprazole magnesium + ASA; esomeprazole/ASA; esomeprazole/acetylsalicylic	Widely Launched	6	ATPase, H+K+ exchanging, alp... prostaglandin-endoperoxide s... prostaglandin-endoperoxide s...	Axanum is a fixed-dose combination (FDC) of esomeprazole and low-dose ASA, developed for the prevention of peptic ulcers associated with low-dose ASA, and for the prevention of cardio- and cerebrovascular events in patients requiring continuous ...	Approvals... on, myocardial, ischaemic Thrombosis, cerebral, Ulc... Ulcer, duodenal (EU app... via the decentralized with Germany acting as re... member state for the prever	<input type="checkbox"/>
65130	omeprazole + cinitapride ER, Zydus	cinitapride ER + omeprazole, Zydus; cinitapride ER/omeprazole, Zydus; omeprazole + cinitapride ER, Zydus; omeprazole/cinitapride ER, Zydus	Ceased	1	5-hydroxytryptamine (seroton)... ATPase, H+K+ exchanging, alp...	Zydus Cadila was developing a fixed-dose combination capsule of omeprazole + cinitapride ER for the treatment of non-ulcer dyspepsia or gastroesophageal reflux disease (GORD) (Clinical Trials Registry India Web Page, 9 Feb 2016).		<input type="checkbox"/>

利用Pharmaprojects巨大数据资源
识别及分析拥有相似化学结构的药物

查询所有已被中止研发的药物化学结构


评估处于研发的新药物组合物

Pharmaprojects

历史研发趋势 (Historical Trends)

查阅及分析药物的历史研发趋势，更好进行预测及战略规划

- 通过药物、类型、作用机制、药用物质、靶点、国家及地区、公司等检索条件分析研发趋势
- 选择通过数据、图表或列表进行显示
- 通过研发阶段或管线、已获批上市或研发中止等条件快速筛选
- 导出至Excel作进一步分析或用于演示



准确分析历年药物研发变化

追踪研发趋势变化

查阅及比较各种药物或类型

调研案例

案例一（Pharmaprojects）：

“如何查阅目前中国处于临床二期及三期的PD-L1药物？”

The screenshot shows the Pharmaprojects search results page. At the top, it displays '7 drugs' and related counts for Trials (619), Investigators (5,660), and Organizations (6,166). The search criteria are visualized in a query builder interface:

- Drug Country is China
- and
- Drug Country Status is Phase III Clinical Trial or Drug Country Status is Phase II Clinical Trial
- and
- Target is PD-L1

Buttons for 'Results', 'Dashboards', and 'Trends' are visible at the top right. Action links include 'Clear Search', 'Share Search', 'Save Search', and 'Create Alert'.




检索条件：

1. 药物国家或地区：“Drug Country”– 选择China
2. 药物国家临床阶段：“Drug Country Status”– 选择Phase II与III
3. 药物靶点：“Target”– 检索PD-L1或PDL1

注：某些靶点或适应症名称可出现相似条件（如：PD-L1或PDL1），结果并无差别并仅方便客户搜索。

案例二（Pharmaprojects）：

“如何查阅所有2017-2018年在中国获批上市的新药（不含适应症扩展）？”



检索条件：

1. 事件类型：“Event Type” – 选择First/New Approval与Launch
2. 事件时间：“Event Date” – 选择2017年至2018年
3. 事件地点：“Event Details” – 输入关键词China（直接筛选事件综述）

案例三 (Trialtrove) :

“如何检索所有在韩国已完成的临床三期胃癌临床试验 (最少500名受试者) ? ”

A collage of various search filters and dropdown menus from the Trialtrove interface. The filters include: Trial Phase (I, II, III, III/IV, IV, Other), Trial Status (Planned, Ongoing, Open, Closed, Temporarily Closed, Terminated, Completed), Disease (Oncology: Gastric), Trial Country (South Korea), and Actual Accrual (Min 500, Max Any).

A screenshot of the Trialtrove search results page. The search criteria are displayed as follows:

- Trial Country is South Korea
- and
- Trial Status is Completed
- and
- Disease is Oncology: Gastric
- and
- Trial Phase is III
- and
- Min Actual Accrual is 500

The results page shows 16 trials, with options for View related: Investigators (715), Organizations (867), and Drugs (17). Navigation buttons include Results, Timeline, Dashboards, and Map. Action buttons include Clear Search, Share Search, Save Search, and Create Alert.

检索条件:

1. **Trial Phase & Status:** 选择“Phase III”与“Completed”
2. **Disease:** 检索并选择 “Oncology: Gastric”
3. **Trial Country:** 检索并选择 “South Korea”
4. **Minimum Enrolment (Actual):** 选择Actual并输入最少为 “500”名受试者

Note: Target Accrual (number of patients sought for) vs. Actual Accrual (number of patients enrolled) – Accrual numbers are based on reported information via the public domain with validation by Trialtrove analyst team. Final accrual information is searchable and provided in the Results table and exports. Interim accrual information is provided within the Trial Profiles when available.

16 trials
View related: [Investigators \(715\)](#) | [Organizations \(867\)](#) | [Drugs \(17\)](#)

Results | Timeline | Dashboards | Map

Clear Search | Stop Search | Save Search | Create Alert

(Trial Country is South Korea) AND (Trial Status is Completed) AND (Trial Phase is III) AND (Disease is Oncology: Gastric) AND (Min Actual Accrual is 500)

Expand Search

Export

Template | Show/Hide columns | 50 results

Trial Title	Protocol/Trial ID	Trial Phase	Trial Status
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine	061 061, Keynote 061-00 15.0378 152988 2015-CT0292 3475-061 3475-061/MK-3475-061/KEYNOTE-061 EudraCT Number: 2014-005241-45 Helsinki Number: 0283-15	III	Completed
A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel versus Placebo Plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric and Gastroesophageal Junction Adenocarcinoma	734 BBI608-336 BRIGHTER CTR20160293 EudraCT Number: 2014-000774-18 IRAS ID: 160335 JapicCTI-142690 NCI-2016-01715 NCRN - 3258 NCT02178956	III	Completed

Show/Hide Columns

Deselect All / Select All

Filter by column name

- Trials
- Trial ID
- Protocol/Trial ID
- Trial Title
- Trial Phase
- Trial Status
- Last Modified Date
- Last Full Review
- Therapeutic Area
- Disease
- Patient Segment
- MeSH Term
- Supporting URLs
- Source

Timeline (2000-2018)

Start Date: 2008/06/04
Enrollment Duration (months): 42.91
Enrollment Close Date: 2012/01/01
Treatment Duration (months): 12.2
Primary Completion Date: 2012/09/24

Actual Accrual: 545
Target Accrual: 535
Reported Sites: 186
Pts/Site/Mo: 0.07

Trial Outcomes (2) Sort Desc

Completed, Negative outcome/pr...	3	6	8	9
Completed, Positive outcome/pr...	5			

Start Date (11) Sort Desc

2008	3
2005	2
2009	2
2013	2
2001	1
2002	1
2006	1
2007	1
2010	1
2014	1
2015	1

Primary Tested Drug (19) Sort Desc

cisplatin	0.75	1.5	2.25	3
doxifuridine	2			
mitomycin C	2			
TS-1	1			
bevacizumab	1			
capecitabine	1			
cetuximab	1			
cisplatin (intraperitoneal)	1			

Sponsor (17) Sort Desc

Roche (F. Hoffmann-La Roche)	2	4	5
(Other Hospital/Academic/Medic...	3		
Asan Medical Center	3		
Roche/Chugai Pharmaceutical	3		
Merck & Co./Merck Sharp & Dohm...	2		
Ulsan University Korea	2		
(Other Cooperative Group)	1		
AstraZeneca	1		

- ✓ 所有数据均可切换至Results, Timeline, Dashboard或Map显示模式
- ✓ 点击“Export”下载至Excel

案例三 (Trialtrove) :

临床试验报告 - 查阅完整临床方案及研究经过

Trial

< Previous 10 / 16 Next >

Back to search

Print Page

Download PDF

Share Trial

Create Alert

A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine

Trial Summary

Trial Outcomes

Trial Objectives

Trial Timing

Patient Population

Trial Locations

Study Keywords

Treatment Plan

Trial Notes

Results

Supporting URLs

Record Updates

Top

Trial Summary

TrialTrove ID	TrialTroveID-252786
Source	Trialtrove
Disease	Esophageal; Gastric
Patient Segment	HER2 positive; Second line; Stage III; Stage IV
MeSH Term	
Trial Tags/Attributes	

Phase	III
Sponsor	Merck & Co./Merck Sharp & Dohme (MSD)
Primary Drugs	pembrolizumab
Other Drugs	paclitaxel

Trial Outcomes

Outcome	Completed, Negative outcome/primary endpoint(s) not met
Outcome Details	December 14, 2017

Treatment Plan

Study Design	Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment An active comparator, 1:1 randomization
Treatment Plan	Arms: Experimental: Pembrolizumab Participants receive pembrolizumab Arms: Active Comparator: Paclitaxel Participants receive paclitaxel & platinum ESMO 2015: Patients will be randomized 1:1 decision. In the pembro arm, pts may continue pembro at the discretion of the central review and per RECIST criteria ASCO 2016: Eligible pts are randomized 1:1

Trial Notes

Enrollment Period: June 4, 2015 - July 26, 2016
<https://www.ncbi.nlm.nih.gov/pubmed/29880231>
[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)31257-1](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31257-1)
2018/07/19
 July 19, 2018 [Sub-group Analysis]
 Presented at the 16th Annual Meeting of Japanese Society of Medical Oncology (JSMO), July 19-21, 2018, Kobe, Japan.
 Abstract Published online: July 19, 2018
 Abstract No.: PS-4
 Kohei Shitara, Kei Muro, Taroh Satah, Takao Tamura, Keisaku Chin, Naomasa Machida, Hiroki Hara, Shuichi Hironaka, Naotoshi Sugimoto, Carlos Mayo, Shi Rong Han, Shinichi Shiratori, Atsushi Ohtsu
KEYNOTE-061: Pembrolizumab vs Paclitaxel for Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Results:
 Overall, 592 pts were enrolled: 395 had PD-L1 CPS >=1 (pembro n=196; PTX n=199). 100 JPN pts were enrolled (pembro n=47; PTX n=53); 65 had PD-L1 CPS >=1 (pembro n=27; PTX n=38). In the CPS >=1 population, median follow-up was 8 mo for all pts and 10 mo for JPN pts. Primary endpoints of median OS and PFS were not statistically significant in all pts (OS, 9.1 vs 8.3 mo with pembro vs PTX [HR 0.82, $P=0.04$]; PFS, 1.5 vs 4.1 mo [HR 1.27, $P=0.58$]). Other P values were nominal. Median OS was 12.3 vs 9.8 mo in JPN pts (HR 0.67, <math>P<0.001</math>); 12-mo OS rates were 40% vs 27% in all pts and 52% vs 34% in JPN pts; 18-mo OS rates were 26% vs 15% in all pts and 26% vs 16% in JPN pts. Median PFS was 1.6 vs 4.2 mo in JPN pts (HR 1.21, <math>P<0.001</math>). ORR was 16% vs 14% in all pts and 7% vs 18% in JPN pts. In the overall population, grade 3-5 drug-related AE rate was 14% vs 35% in all pts and 4% vs 44% in JPN pts; treatment was discontinued for drug-related AEs in 3% vs 5% of all pts and 0% vs 6% of JPN pts.
Conclusion: Pembro (vs PTX) reduced risk for death by 18% in all pts and by 33% in JPN pts with previously treated G/GEJ cancer and PD-L1 CPS >=1. Pembro had a better safety profile than PTX in all pts and in JPN pts.
https://www.micenevi.jp/jsmo2018/researchdetail_program/4541
2018/05/25
 Mexico Clinical Trial Registry [Accessed on: May 25, 2018]
 [Translated from Spanish]
 PROTOCOL NUMBER:MK-3475-061
 SPONSOR:Merck Sharp & Dohme Corp.
FULL TITLE OF STUDY: "Phase III, open-label, randomized clinical study of Pembrolizumab (MK-3475) compared to Paclitaxel in patients with gastric adenocarcinoma or advanced gastroesophageal junction that worsened after first-line treatment with Platinum and Fluoropyrimidine".

案例四 (Sitetrove) :

“如何找出目前常驻韩国并拥有临床三期胃癌临床研究经历的最佳人选？”

The screenshot displays the Sitetrove search interface. At the top, it shows '17 investigators' and options to view related 'Trials (31)', 'Organizations (38)', and 'Drugs (38)'. There are buttons for 'Results', 'Dashboards', and 'Map'. Below this, there are links for 'Clear Search', 'Share Search', 'Save Search', and 'Create Alert'. The search criteria are displayed in two rows:

- Row 1: Disease is Oncology: Gastric, and Trial Status is Completed, and Trial Phase is III.
- Row 2: Investigator Tier is 1, and Investigator Country is Republic of Korea.

On the left, there is a sidebar with a list of filter categories. The 'Investigator' category is expanded, showing various fields like Full Name, Last Name, Specialty, Last Trial Start Date, Investigator ID, NPI Number, Location, Investigator City, Investigator State, Investigator Country (highlighted), Investigator Region, Investigator Post Code, Investigator Radius, Regulatory, and Last Reg. Action.

Below the sidebar, there are two inset windows:

- The first inset shows the 'Investigator Tier' filter dropdown menu with 'is' selected and '1' entered in the input field, and an 'Apply' button.
- The second inset shows the 'Investigator Country' search results, with 'korea' entered in the search box and 'Republic of Korea' listed as a result.

检索条件:

- Trial Phase & Status:** 选择 “Phase III” 与 “Completed”
- Trial Disease:** 检索及选择 “Oncology: Gastric”
- Investigator Country:** 检索及选择 “South Korea”
- Investigator Tier:** 输入 “1” 筛选出 1 级 (Tier 1) 研究人员

Note:
Investigator Tier – The Sitetrove team has developed a proprietary investigator prioritization algorithm which provides an objective method for determining the potential attractiveness of investigators for participation in clinical trials. This algorithm incorporates aspects of overall trial experience, recentness of activity, and user’s search parameters within a given disease.

For more information:

分级排行说明 – <https://citeline.informa.com/investigators/column-info/investigatorDiseaseTier>
分级排行使用介绍 – <https://citeline.zendesk.com/hc/en-us/articles/360009648973-How-do-I-prioritize-investigators-in-Sitetrove->

客服支持

顶级客服团队鼎力相助

产品培训

- 订制或多人培训
- 特定部门实际应用培训
- 基础培训
- 订制培训
- 高级培训（含实际各类信息进阶操作）
- 线下视频、短片及常见答疑
- 现场培训（需10名或以上）

使用辅助

- 一般咨询
- 产品使用问题
- 个性化技术支持
- 数据导出或使用辅助支持或培训
- 用户反馈

联络方式 – client.services@citeline.com

亚太区客服 – Robert.wu@informa.com

关键辅助链接 – Citeline Help Center ([点击查阅](#))

■ 各产品涵盖范围

- Trialtrove & Sitetrove 疾病涵盖说明 – <https://citeline.zendesk.com/hc/en-us/categories/360000327534-Trialtrove-and-Sitetrove-Disease-Scope-Statements>
- Pharmaprojects 内容涵盖说明 – <https://citeline.zendesk.com/hc/en-us/articles/360007579834-Pharmaprojects-Scope-Statement>

■ 用词释义

- Trialtrove & Sitetrove Study Keyword 释义 – <https://citeline.zendesk.com/hc/en-us/articles/360017923593-Trialtrove-Sitetrove-Study-Keyword-Definitions>
- Trialtrove & Trialpredict Category 释义 – <https://citeline.zendesk.com/hc/en-us/articles/360006300933-Trialtrove-Trialpredict-Sitetrove-Glossary-Category-Definitions->
- Pharmaprojects 用词释义 (一般) – <https://citeline.zendesk.com/hc/en-us/articles/360008401514-Pharmaprojects-Glossary-General>
- Pharmaprojects 事件一览及释义 – <https://citeline.zendesk.com/hc/en-us/articles/360008402554-Pharmaprojects-Glossary-Drug-Events>

■ 关键功能教程

- 基础使用 – <https://citeline.zendesk.com/hc/en-us/sections/360000990334-General-Citeline-Functionality>
- Sitetrove – <https://citeline.zendesk.com/hc/en-us/sections/360000819674-Sitetrove>
- Pharmaprojects – <https://citeline.zendesk.com/hc/en-us/sections/360000990354-Pharmaprojects>
- Trialpredict – <https://citeline.zendesk.com/hc/en-us/sections/360000819854-Trialpredict-Trial-Timing-Data>
- BizInt Smart Charts – <https://citeline.zendesk.com/hc/en-us/sections/360001764533-BizInt-Pharmaprojects-Trialtrove>

■ 分析师提示

- Trialtrove – <https://citeline.zendesk.com/hc/en-us/sections/360002365814-Trialtrove-Analyst-Tips>
- Sitetrove – <https://citeline.zendesk.com/hc/en-us/sections/360002387573-Sitetrove-Analyst-Tips>
- Pharmaprojects – <https://citeline.zendesk.com/hc/en-us/sections/360002365854-Pharmaprojects-Analyst-Tips>

■ 线上教程视频

- Trialtrove 基础教程 – <https://citeline.zendesk.com/hc/en-us/articles/360007613553-Welcome-to-Trialtrove-recorded-training-link-July-2018-10-minutes>
- Sitetrove 基础教程 – <https://citeline.zendesk.com/hc/en-us/articles/360007513034-Welcome-to-Sitetrove-recorded-training-link-July-2018-9-minutes>
- Pharmaprojects 基础教程 – <https://citeline.zendesk.com/hc/en-us/articles/360005354894-Welcome-to-Pharmaprojects-demo-5-minutes>
- 自动邮件提醒设置 – <https://citeline.zendesk.com/hc/en-us/articles/360006039174-Watches-and-Alerts-recorded-link>
- Citeline 临床调研及可行性分析 – <https://citeline.zendesk.com/hc/en-us/articles/360015534754-Using-Citeline-for-Clinical-Operations-and-Feasibility-recorded-training-link-29-Min>